** Shares of drug developer Pliant Therapeutics PLRX.O fall 65.5% to $2.72 in extended trading
** Company says a mid-stage trial testing experimental drug bexotegrast in patients with idiopathic pulmonary fibrosis has been paused
** Says enrollment and dosing has been paused while a Data Safety Monitoring Board (DSMB) reviews its trial data
** A DSMB refers to an independent group of experts that reviews clinical trial data to ensure the safety of participants and the validity of the trial
** Idiopathic pulmonary fibrosis is a chronic lung disease that causes scarring and stiffening of the lung tissue
** Up to last close, stock down 40.9% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。